Orion Oyj (OTCMKTS:ORINY) Releases Earnings Results

Orion Oyj (OTCMKTS:ORINY) issued its quarterly earnings data on Tuesday. The company reported $0.28 EPS for the quarter, Zacks reports. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%.

Orion Oyj Stock Performance

Shares of OTCMKTS ORINY opened at $27.03 on Tuesday. Orion Oyj has a 12-month low of $17.50 and a 12-month high of $28.55. The firm has a market capitalization of $7.63 billion, a price-to-earnings ratio of 21.45 and a beta of 0.25. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The firm has a 50 day moving average of $24.65 and a 200 day moving average of $25.07.

Analysts Set New Price Targets

Separately, Nordea Equity Research cut Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.